June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Tolerability of a Shape Changing Intravitreal Hydrogel Depot
Author Affiliations & Notes
  • Arthur Driscoll
    Ocular Therapeutix, Bedford, Massachusetts, United States
  • Charles D Blizzard
    Ocular Therapeutix, Bedford, Massachusetts, United States
  • Jonathan H Talamo
    Ocular Therapeutix, Bedford, Massachusetts, United States
  • Peter K Jarrett
    Ocular Therapeutix, Bedford, Massachusetts, United States
  • Rami F Elhayek
    Ocular Therapeutix, Bedford, Massachusetts, United States
  • Tim Jarrett
    Ocular Therapeutix, Bedford, Massachusetts, United States
  • Zach Lattrell
    Ocular Therapeutix, Bedford, Massachusetts, United States
  • Michael McGrath
    Ocular Therapeutix, Bedford, Massachusetts, United States
  • Stephen Takach
    Ocular Therapeutix, Bedford, Massachusetts, United States
  • Amar Sawhney
    Ocular Therapeutix, Bedford, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Arthur Driscoll, Ocular Therapeutix (E); Charles Blizzard, Ocular Therapeutix (E); Jonathan Talamo, Ocular Therapeutix (E); Peter Jarrett, Ocular Therapeutix (E); Rami Elhayek, Ocular Therapeutix (E); Tim Jarrett, Ocular Therapeutix (E); Zach Lattrell, Ocular Therapeutix (E); Michael McGrath, Ocular Therapeutix (E); Stephen Takach, Ocular Therapeutix (E); Amar Sawhney, Ocular Therapeutix (E)
  • Footnotes
    Support  Ocular Therapeutix supported this research.
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1980. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Arthur Driscoll, Charles D Blizzard, Jonathan H Talamo, Peter K Jarrett, Rami F Elhayek, Tim Jarrett, Zach Lattrell, Michael McGrath, Stephen Takach, Amar Sawhney; Tolerability of a Shape Changing Intravitreal Hydrogel Depot. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1980.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : We evaluated the tolerability of a shape changing bioabsorbable hydrogel in Dutch belted rabbits. This hydrogel can be used as a vehicle for the sustained delivery of tyrosine kinase inhibitors (TKI) as well as large molecule anti-VEGF agents delivered via intravitreal injection in Dutch belted rabbits through 6 months.

Methods : Eighteen eyes of naïve Dutch belted rabbits (n=9) were bilaterally dosed with the vehicle control at Day 0. Biweekly slit lamp, IOP, and posterior segment exams were performed. Monthly OCT was performed, and fluorescein angiography (FA), infrared fundus photography and electroretinography (ERG) were obtained at Months 1, 3 and 6. Eyes were enucleated at each time point (n=6) for histopathological evaluation.

Results : Serial clinical examinations showed no sign of inflammatory response or other abnormalities. No clinically-significant changes in IOP, OCT, ERG or FA were observed. Infrared fundus photography showed increasing translucency and shrinkage of depot size over time. At 1, 3 and 6 months, histopathologic analysis demonstrated minimal changes from baseline in cornea, conjunctiva, sclera, choroid, retina, and vitreous humor. Evidence of depot material was present at all time points.

Conclusions : The shape changing hydrogel appears well-tolerated in a DB rabbit model. In addition to an absence of clinical findings suggestive of immunoreactivity, light microscopy of tissue sections and OCT imaging showed minimal to no evidence of inflammatory response or abnormal chorioretinal morphology. Infrared fundus photography findings were consistent with depot resorption through 6 months.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

Histopathologic analysis demonstrated minimal to no vitreal, retinal or scleral inflammation, or fibrosis around the injected material

Histopathologic analysis demonstrated minimal to no vitreal, retinal or scleral inflammation, or fibrosis around the injected material

 

Infrared fundus photography showed increasing shrinkage of depot size over time. OCT shows normal chorioretinal morphology through 6 months. In some cases, hydrogel was not present at the 6 month time point

Infrared fundus photography showed increasing shrinkage of depot size over time. OCT shows normal chorioretinal morphology through 6 months. In some cases, hydrogel was not present at the 6 month time point

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×